Cargando…
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing st...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V. and International Society of Chemotherapy.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128600/ https://www.ncbi.nlm.nih.gov/pubmed/32259575 http://dx.doi.org/10.1016/j.ijantimicag.2020.105967 |